Company Logo Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2020-2024" report has been added to ...

Fortress Biotech, Inc. has announced the acquisition of its subsidiary Checkpoint Therapeutics, Inc. by Sun Pharmaceutical Industries Limited, which closed on May 30, 2025, after receiving ...

As we hit the middle of the year, large-scale pharmaceutical acquisitions are well underway. Patterns we have looked into in previous entries continue including the availability of huge amounts of ...

After a drawn-out acquisition ... U.K. biotech F-star Therapeutics is charting its own path as a private, independent company. The antibody-focused biotech is breaking free from invoX Pharma ...

Biotechnology startups historically have relied on top pharmaceutical companies to make acquisition bids. Now a new class of buyers is emerging. Smaller drugmakers increasingly are joining the ...

Royalty Pharma plc (NASDAQ:RPRX), a leading funder of innovation across the biopharmaceutical industry with a market capitalization of $19.25 billion and an impressive 99% gross profit margin ...

As major pharmaceutical companies began pursuing acquisitions, investor interest surged in late 2023 and early 2024. However, the momentum soon faded, leading to a stagnation in biotech stocks.

The acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023 and is expected to be completed in the first half of 2025. Under the terms of the ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition ... small and mid-cap biotechnology companies to ...

The introduction of COVID-19 vaccinations in 2020 caused the biotech industry to soar to prominence. As Big Pharma started investing in acquisitions, investor interest increased in late 2023 and ...